Offer Closed Cannatrek Ltd

OnMarket | Cannatrek Limited

Fixed Priced RestrictedType of Offer
11 Sep 19Offer Open
30 Sep 19Pay By
Up to $10 millionSize of Offer
$10,000 Minimum Investment
Company ledLead Manager


This is a restricted offer and is only open to Professional, Sophisticated and Experienced investors.  More information on how to qualify here.

Minimum application size of $10,000. 

Company Update

Cannatrek is please to provide a Company Update detailing the following:

  • Their first medicinal cannabis seeds (‘Lot 1’) were planted at the UL01 cultivation facility in late August and are now established plants. Lot 1 is part of a series of breeding harvests that will be used to provide stable mother stock, supporting commercial medicinal cannabis production
  • Dr Susan Pond has joined the Cannatrek board as a non-executive Director. Susan is an experienced company director, including former CEO and Director of Johnson & Johnson Research
  • Their dedicated medical access support team has now helped doctors and patients access over 1,000 units of Cannatrek’s low cost medicinal cannabis products

The full Company Update is available here


Cannatrek Limited is an Australian based medicinal cannabis company, developing production, manufacturing and distribution assets across Australia. The Company is uniquely placed in the high-growth global medicinal cannabis industry, with a strong asset base, granted licenses and permits, revenues, and an outstanding team. 

Cannatrek is one if the first companies in Australia to be issued the full suite of medicinal cannabis licences, including Cannabis Research (RL002/18), Medicinal Cannabis Production, Manufacture, Import and Export Licences and National Distribution licences state by state. 

The Company has also recently been awarded a permit to commence growing medicinal cannabis at its 3,200m2 climate-controlled greenhouse in southern Queensland. At full capacity, Cannatrek will have a perpetual harvest facility near the central Victorian city of Shepparton, for which development approval has already been received. The 160,000m2 facility will make Cannatrek one of the world’s largest producers of medicinal cannabis. 

With economies of scale, Cannatrek will be a low-cost producer of high-quality medicinal cannabis that will be available to consumers in Australia and overseas, via a vertically integrated “from seed to patient” business model.

The business began in 2015, receiving one of the first medicinal cannabis licences from the Australian Federal Government.  Cannatrek is an unlisted public company with three years of audited financial results.  It complies with corporate governance regulations, and has an experienced board of directors, operational team and scientific/medical advisory panel with deep industry expertise. 

Investment Highlights

  • From "seed to patient" – fully integrated medicinal cannabis business model across all aspects of the value chain
  • Market leading position – one of the first companies to be issued with full suite of federal and state government medicinal cannabis licences 
  • Operational growing facility – operational 3,200m2 research and production facility in Queensland, and planned development of 160,000m2 glasshouse facility in Victoria
  • Market access – Patient access hub via Cannahealth, providing access to patients, doctors and pharmacists
  • Strategic research partnerships – undertaking clinical trials with some of Australia’s leading hospitals, universities and research institutes testing the effects of CBD on schizophrenia, anxiety and post-traumatic stress disorder (PTSD) 
  • Existing revenues – revenues of ~$100k via sale of imported medicinal cannabis products, looking to increase to $550k-$1m in FY2020
  • Large addressable market - global medical cannabis market of ~US$11.7B in 2018 and is expected to grow to around US$148.35B p/a by the end of 2026
  • Guided by an experienced board and management team with expertise across all aspects of the medicinal cannabis value chain

Offer overview

Cannatrek is looking to raise up to $10m via this offer, with the ability to take oversubscriptions for up to $5 million. Applications are for ordinary shares, at an issue price of $0.40 per share, giving the company a pre-money valuation of $65 million.

Funds raised under the offer will be applied to:

  • Phase 1 of the 160,000m2 Shepperton glasshouse facility
  • Sales/marketing and business development
  • Further enhance the existing IT platform
  • General working capital, including human resources

Cannatrek has an intention to list on ASX in mid-2020 raising $40-50 million via an IPO. Funds from the IPO would be predominately used to further the development of the 160,000m2  Shepperton facility.

For more information see the Term Sheet.

Market opportunity – global and in Australia

The global medicinal cannabis market was approximately US$11.7B in 2018 and is expected to grow to around US$148.35B per annum by the end of 2026 – a growth rate of 26.4% per annum.  The legal cannabis market has had significant growth since the relaxation of rules worldwide to permit its use.  Several states in the US have legalised recreational consumption, Canada legalised recreational consumption in October 2018, and other countries like the UK and Germany have legalised it for medicinal use.  Recreational use in markets such as Canada is placing pressure on supply of medicinal cannabis.  Consequently, there is a need for high-quality products with known components, cultivated at large scale for consistent, reliable supply in many markets.

Australia can be one of the key supply centres of for APAC and world markets due to its advantageous climate conditions and excellent clean green standards. 

In Australia, nearly all medicinal cannabis is imported, making it expensive.  Since 2016, several Australian states have legalised access to medicinal cannabis via the Special Access Scheme (SAS), allowing patient prescriptions. This has led to significant growth in the number of approvals, as shown in the chart below.  This is expected to reach over 20,000 by the end of 2019.

Total TGA Special Access Scheme Approvals


Market Access

A key success factor for any medicinal cannabis producer is to have platforms to access patients, doctors and pharmacists.  Cannahealth is Cannatrek’s Patient Access hub spot.  It is being rolled out nationally to develop trusted support networks for the supply of quality medicinal cannabis products for GPs, participating pharmacists, carers and an estimated 300-500,000 eligible patients currently in Australia.


Cannatrek currently has two production sites.  The first, UL01, is located in southern Queensland and has 3,200m2 of growing area.  Commissioning has been completed and has recently received the research permit to begin growing.  Annual production will be up to 5 tonnes. 

Aerial view of UL01 Qld

The primary commercial site, UL02, will be based on 178 acres of land recently purchased near Shepparton. Local council Development Approval (DA) has been received to commence construction of the facility on a staged basis.  The facility will eventually include 160,000 m2 of growing area under a giant high-tech glasshouse.  When completed, annual production will be 160-200 tonnes.

Detailed schematic of UL02 Vic


Digital aerial view of UL02 Vic

Strategic partners

In January, Cannatrek received a financial grant and industry support from the Victorian State Government to develop the Shepparton site and create over 200 jobs that would support regional industry. 

Cannatrek also has a Memorandum of Understanding (MoU) with La Trobe University to assist with research, education and plans for a patient access call-centre facility.  The company is in discussions with numerous parties regarding offtake supply agreements.


The company plans to commence two ground-breaking clinical trials in mental health – one on the therapeutic effects of Cannabidiol (CBD) on schizophrenia with a leading Victorian hospital, and another on anxiety and post-traumatic stress syndrome (PTSD) for military veterans and first responders with a leading research institute.
The company is finalising its application for Major Project Status (MPS) from the Federal Government that will prioritise any pending and future medicinal cannabis licenses/permits once it has been granted MPS. This would establish Cannatrek as a leading project in the nascent Australian medicinal cannabis industry.


You are encouraged to read the Investor Presentation and Term Sheet carefully as they contain important information about the Company and the Offer. Like all investments, an investment in the Company carries risk. As set out on page 2 of the Term Sheet, Cannatrek Ltd is subject to a range of risks, including but not limited to; being an early stage company in a new industry, the requirement for additional funding, construction risk and agricultural risks associated with cannabis cultivation.


Section 708 disclosure: The Investor Presentation and Term Sheet are issued by Cannatrek Ltd ACN 056 175 369 (“Cannatrek”), and OnMarket makes no representation as to their accuracy or completeness. The purpose of these documents is to provide information for prospective investors to decide whether they wish to invest in Cannatrek. These are important documents. Recipients should read these documents in their entirety before making a decision to invest and, if in doubt, should consult their professional advisors.

This Investor Presentation and Term Sheet are intended to provide potential investors with information only and does not constitute a prospectus, short form prospectus or other disclosure document as defined in the Corporations Act 2001 (Cth) (“the Act”). These documents have not been lodged with the Australian Securities and Investments Commission ("ASIC") or any other government body. The offer made under this Investor Presentation and Term Sheet is only available for persons who qualify as sophisticated or experienced investors (as defined in s708(8)-(10) of the Act), professional investors (as defined in s708(11) of the Act), investors to whom personal offers are made under s708(1), or investors to whom disclosure is otherwise not required under Part 6D of the Act (collectively, “Qualified Investors”). Cannatrek will not issue any shares under this offer to a person unless it is satisfied that the person is a Qualified Investor.

You should read the Important Notice on page 2 of the Investor Presentation before making a decision whether to invest.





Discover investment opportunities here

Tap 'More Info' to get access to free research, all company releases, and invest instantly for shares.

IPO Live

Tartana Resources Ltd ASX: TNA

Tartana Resources Ltd
Copper-zinc resources exploration company, projects in Queensland and Tasmania


Tartana Resources Limited (ASX: TNA) is focusing on copper and zinc, two commodities which are highly leveraged to economic growth, particularly in China and the electric vehicle revolution. Tartana Resources has two key project areas, the Tartana Copper/Zinc project in near Chillagoe in north QLD and the Zeehan Zinc Slag project in western TAS – all on granted mining leases. These projects offer potential for cash flow generation, as well a significant exploration appeal with porphyry copper targets.

$4m - $6mSize of Offer
04 Jul 19Offer Open
21 Oct 19Pay By
IPO OnMarket Bidding Closed

Cronos Australia Ltd ASX: CAU

Cronos Australia Ltd
Licensed medicinal cannabis company targeting the domestic and Asia Pacific markets


The Cronos Australia Ltd IPO has closed for applications via OnMarket. Applications must be funded by 16 October, at 5pm


Cronos Australia Ltd (ASX:CAU) was formed to take advantage of opportunities relating to the emerging medicinal cannabis industry both domestically and in the Asia Pacific region. Having secured all the necessary Australian licences to operate – including import and export licences, Cronos Australia’s vision is to become a leading health and wellness company in the Asia Pacific region through the distribution of premium cannabis products.


Cronos Australia was established as a joint venture with global cannabinoid company, Cronos Group Inc (market cap. of approx. A$4.53bn). Under a licence agreement with Cronos Group Inc, Cronos Australia has access to certain intellectual property, know-how, and trademarks.

$20 millionSize of Offer
08 Oct 19Offer Open
16 Oct 19Pay By
IPO Closed Sep 2019

Trigg Mining Ltd ASX: TMG

Trigg Mining Ltd

Trigg Mining Limited is a mineral exploration company focussed on developing a sustainable sulphate of potash (SOP) mine in WA. SOP is an essential fertiliser needed for global food production of high value crops and human nutrition.

Fully Funded
$4.5 millionSize of Offer
CPS Capital Group Lead Manager
IPO Closed Aug 2019

Imricor Medical Systems, Inc. ASX: IMR

Imricor Medical Systems, Inc.

Imricor Medical Systems, Inc. is an innovative US based medical device company that aims to develop the world’s first commercially viable and safe MRI-compatible devices for cardiac catheter ablation procedures. 

Fully Funded
$12.1 millionSize of Offer
Moelis Australia Lead Manager
Placement Closed Jul 2019

Althea Group Holdings Ltd ASX: AGH

Althea Group Holdings Ltd

Althea Group Holdings Ltd is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis. Althea operates within highly regulated medicinal cannabis markets including Australia, the United Kingdom and Canada.

Fully Funded
$30 millionSize of Offer
Pac Partners Lead Manager
IPO Closed Jul 2019

AppsVillage Australia Ltd ASX: APV

AppsVillage Australia Ltd

AppsVillage Australia Ltd is a fast-growing software-as-a-service (SaaS) company capitalising on the growing use of mobile applications and the strong demand for mobile digital marketing solutions for small-medium businesses (SMBs). 

Fully Funded
$5 millionSize of Offer
RM Corporate Finance Lead Manager
IPO Closed Jul 2019

RPM Automotive Group Ltd ASX: RPM

RPM Automotive Group Ltd

RPM Automotive Group Ltd is a collection of businesses operating within the Australian automotive sector, offering customers a range of products & services, including; tyres for commercial & passenger vehicles, vehicle servicing & repairs, roadside assistance, motor-accessories and motorsport safety gear.

Fully Funded
$2.6 millionSize of Offer
Novus Capital Lead Manager
IPO Closed Jul 2019

Mandrake Resources Ltd ASX: MAN

Mandrake Resources Ltd

Mandrake Resources Limited is a gold and base metals exploration company focussed on exploring and developing identified gold mineralisation at its drill ready Pine Creek Berinka project, located 220km south west of Darwin in the Northern Territory. 

Fully Funded
$4.5 millionSize of Offer
Ironside Capital Lead Manager
IPO Closed Jun 2019

NZ Coastal Seafoods Ltd ASX: NZS

NZ Coastal Seafoods Ltd

New Zealand Coastal Seafoods Limited is a processor, distributor and exporter of premium seafood products. NZCS’ products are sold, directly and through distributors, to customers, restaurants, seafood traders, supermarkets and other retailers in New Zealand, Australia and Asia. 

Fully Funded
$5 millionSize of Offer
Patersons Securities Lead Manager